Clinical trials: insulin glargine
Type 2 Diabetes Mellitus, Renal Impairment
Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment
The TRENT trial is designed to confirm the efficacy and safety of Gla-300 compared with IDeg-100 in insulin-naïve patient (participants who have not tried insulin) with Type 2 Diabetes Mellitus (T2DM) and renal impairment.
- Trial name
- TRENT (NCT05552859)
- Testing
- Insulin glargine 300 U/mL, Insulin degludec 100 U/mL
- Where
- 68 sites in United States, Czechia and 3 more
- Volunteers
- 62 people
- Sponsor
- Sanofi
Type 2 Diabetes, T2D
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)
The main purpose of this study is to determine the efficacy and safety of insulin efsitora alfa (LY3209590) administered weekly using a fixed dose escalation compared to insulin glargine in adults with type 2 diabetes (T2D) who…
- Trial name
- QWINT-1 (NCT05662332)
- Testing
- Insulin Efsitora Alfa, Insulin Glargine
- Where
- 71 sites in United States, Argentina and 2 more
- Volunteers
- 795 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
It has been shown that individuals with type 2 diabetes have higher blood sugar throughout the night than individuals without type 2 diabetes.
- Trial name
- NCT05098470
- Testing
- Metformin, Insulin Glargine, Dorzagliatin
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Alabama at Birmingham
Type 1 Diabetes
Impact of Introducing Basaglar Insulin to the Treatment Regimen of Youth With Diabetes in Pakistan
This study aimed to determine the effect of introducing Basaglar and insulin pen injection devices on clinical and quality of life (QOL) parameters in children and young adults with type 1 diabetes in Pakistan
- Trial name
- NCT06717191
- Testing
- biosimilar insulin glargine
- Where
- Pakistan
- Volunteers
- 296 people
- Sponsor
- Life for a Child Program, Diabetes Australia
Type 1 Diabetes Mellitis
Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients
The goal of this clinical trial is to demonstrate the non-inferior immunogenicity of GP40321 compared to Apidra® SoloStar® at a concentration of 100 U/mL in type 1 diabetes mellitus patients.
- Trial name
- NCT07070752
- Testing
- GP40321, Apidra® SoloStar®, RinGlar®
- Where
- 17 sites in Russia
- Volunteers
- 224 people
- Sponsor
- Geropharm
Diabetes Mellitus Type 2
HbA1c Variability in Type II Diabetes
There are numerous possible reasons why it could be speculated that HbA1c variability may affect complication risk. Of interest are the concepts that both laboratory and clinic evidence suggests that periods of sustained…
- Trial name
- NCT02879409
- Testing
- Metformin, Gliclazide, Sitagliptin
- Where
- Qatar
- Volunteers
- 150 people
- Sponsor
- Weill Cornell Medical College in Qatar
Diabetes Mellitus, Type 2
Remote And Decentralised Innovative Approaches to Clinical Trials (RADIAL)
Pan-European proof-of-concept study comparing Decentralised Clinical Trial (DCT) and hybrid approaches to conventional clinical trial approaches in patients with Type 2 diabetes mellitus treated with Toujeo®.
- Trial name
- RADIAL (NCT05780151)
- Testing
- Methodological intervention, Toujeo
- Where
- 9 sites in Denmark, Germany and 1 more
- Volunteers
- 107 people
- Sponsor
- Mira Zuidgeest
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Afrezza® INHALE-1 Study in Pediatrics
INHALE-1 is a Phase 3, open-label, randomized clinical study evaluating the efficacy and safety of Afrezza in combination with a basal insulin (i.e., the Afrezza group) versus insulin aspart, insulin lispro or insulin glulisine…
- Trial name
- INHALE-1 (NCT04974528)
- Testing
- Afrezza, Rapid-acting Insulin Analog, Basal Insulin
- Where
- 39 sites in United States
- Volunteers
- 319 people
- Sponsor
- Mannkind Corporation
Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections
The reason for this study is to evaluate if the once-weekly study drug insulin efsitora alfa (LY3209590) is safe and effective compared with daily insulin glargine in participants with Type 2 diabetes (T2D) that have already been…
- Trial name
- QWINT-4 (NCT05462756)
- Testing
- Insulin Efsitora Alfa, Insulin Lispro (U100), Insulin Glargine (U100)
- Where
- 81 sites in United States, Argentina and 6 more
- Volunteers
- 730 people
- Sponsor
- Eli Lilly and Company
Type2diabetes
Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control
In this study, we aim to explore the beneficial effect of early short-term (two weeks), self-titrated, basal-only insulin therapy on the degree of glycemic control over 1-year follow through a prospective cohort.
- Trial name
- NCT06107153
- Testing
- Insulin Glargine 100 UNT/ML Pen Injector [Lantus], Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg, Pioglitazone 30mg
- Where
- Iraq
- Volunteers
- 243 people
- Sponsor
- University of Basrah
Type 2 Diabetes Mellitus
To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.
The study aims to evaluate the efficacy and safety of INS068 once daily (QD) in subjects with type 2 diabetes not adequately controlled with basal insulin compared to insulin Glargine QD for 26weeks.
- Trial name
- NCT05702073
- Testing
- INS068 injection, Insulin Glargine
- Where
- China
- Volunteers
- 423 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs
The study is being conducted to evaluate the efficacy and safety of INS068 once daily (QD) in subjects with type 2 diabetes not adequately controlled with oral antidiabetic drugs compared to insulin Glargine QD for 26+26 weeks.
- Trial name
- NCT05699408
- Testing
- INS068 injection, Insulin Glargine
- Where
- China
- Volunteers
- 513 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes Patients, Overweight and Obesity
Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)
The present 24-week, prospective, open-label, randomized, multicenter, parallel group trial is carried to investigate and evaluate the efficacy and safety of Liraglutide in combination with prandial insulin therapy vs insulin…
- Conditions
- Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic)
- Trial name
- LiraGooD (NCT03087032)
- Testing
- Liraglutide, insulin glargine
- Where
- China
- Volunteers
- 164 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Type 2 Diabetes
Degludec Glargine U300 Hospital Study
Limited data exist about the use of insulin degludec and insulin glargine U300 in the hospitalized patients. A previous study compared the safety and efficacy of insulin degludec versus insulin glargine U100 for the management of…
- Trial name
- NCT05036876
- Testing
- Degludec, Glargine U300
- Where
- India
- Volunteers
- 220 people
- Sponsor
- Medanta, The Medicity, India
Gestational Diabetes, Pregnancy Related
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)
The aim of our study is to compare neonatal and maternal outcomes using different thresholds for the initiation and titration of pharmacotherapy for gestational diabetes (GDM).
- Trial name
- START2 (NCT06419803)
- Testing
- Insulin
- Where
- 2 sites in United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Gestational Diabetes, Pregnancy Related
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes
The aim of our study is to compare neonatal and maternal outcomes using different thresholds for the initiation and titration of pharmacotherapy for gestational diabetes (GDM).
- Trial name
- START 1 (NCT06419777)
- Testing
- Insulin
- Where
- 2 sites in United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Type I Diabetes
Evaluating the Impact of Introducing Basaglar, a Long-acting Analog Insulin, on Clinical and Quality of Life Outcomes in Youth with Diabetes in Bangladesh
This study aimed to determine the effect of introducing Basaglar and insulin pen injection devices on clinical and quality of life (QOL) parameters in children and young adults with type 1 diabetes in Bangladesh
- Trial name
- NCT06674135
- Testing
- biosimilar insulin glargine
- Where
- Bangladesh
- Volunteers
- 202 people
- Sponsor
- Life for a Child Program, Diabetes Australia
Type 1 Diabetes (T1D)
Introducing Biosimilar Insulin Glargine to the Treatment Regimen of Children and Youth with Type 1 Diabetes in Mali
This study aimed to evaluate the impact on blood glucose control and quality of life in children and youth with type 1 diabetes in Mali by switching the insulin regimen from human insulin via needle and syringe, to long-acting…
- Trial name
- NCT06624943
- Testing
- biosimilar insulin glargine
- Where
- Mali
- Volunteers
- 260 people
- Sponsor
- Life for a Child Program, Diabetes Australia
Diabetes Mellitus in Pregnancy, Type 2 Diabetes Mellitus (T2DM)
RCT Glargine vs NPH for Treatment of DM in Pregnancy
We are asking you to take part in this research study because you are diagnosed with pregestational Type 2 Diabetes Mellitus or Gestational Diabetes Mellitus requiring insulin therapy in pregnancy.
- Conditions
- Diabetes Mellitus in Pregnancy, Type 2 Diabetes Mellitus (T2DM), Gestational Diabetes Mellitus, Class A2
- Trial name
- NCT06619301
- Testing
- Insulin glargine, insulin NPH
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Loyola University
Diabetes
Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM
Type 2 diabetes is a systemic metabolic disease with significant morbidity and mortality due to damaging blood vessels. Increased blood sugar level is a hallmark of diabetes and is an contributes to the development of many of its…
- Trial name
- NCT01107717
- Testing
- metformin\pioglitazone\exenatide, metformin, glyburide and glargine
- Where
- United States
- Volunteers
- 318 people
- Sponsor
- The University of Texas Health Science Center at San Antonio